Sarcoma treatment in the era of molecular medicine
CNR Ibb | back to homepage
CNR Ibb | back to homepage

Sarcoma treatment in the era of molecular medicine (147 views)

Grünewald TG, Alonso M, Avnet S, Banito A, Burdach S, Cidre-aranaz F, Di Pompo G, Distel M, Dorado-garcia H, Garcia-castro J, González-gonzález L, Grigoriadis AE, Kasan M, Koelsche C, Krumbholz M, Lecanda F, Lemma S, Longo DL, Madrigal-esquivel C, Morales-molina Á, Musa J, Ohmura S, Ory B, Pereira-silva M, Perut F, Rodriguez R, Seeling C, Al Shaaili N, Shaabani S, Shiavone K, Sinha S, Tomazou EM, Trautmann M, Vela M, Versleijen-jonkers YM, Visgauss J, Zalacain M, Schober SJ, Lissat A, English WR, Baldini N, Heymann D

Embo Mol Med (ISSN: 1757-4676linking), 2020 Oct 13; 12(11): e11131-N/D.

Export to BibTeX    Export to EndNote

Paper type: Journal Article, Review,

Impact factor: 10.293, 5-year impact factor: 0

Url: Not available.

Keywords: Bone Sarcoma, Molecular Diagnostics, Molecular Medicine, Soft Tissue Sarcoma, Targeted Therapy,

Affiliations:
*** IBB - CNR ***

Max-Eder Research Group for Pediatric Sarcoma Biology, Institute of Pathology, Faculty of Medicine, LMU Munich, Munich, Germany.
Division of Translational Pediatric Sarcoma Research, German Cancer Research Center (DKFZ), Hopp Children's Cancer Center (KiTZ), German Cancer Consortium (DKTK), Heidelberg, Germany.
Institute of Pathology, Heidelberg University Hospital, Heidelberg, Germany.
Program in Solid Tumors and Biomarkers, Foundation for the Applied Medical Research, University of Navarra Pamplona, Pamplona, Spain.
Orthopedic Pathophysiology and Regenerative Medicine Unit, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy.
Pediatric Soft Tissue Sarcoma Research Group, German Cancer Research Center (DKFZ), Heidelberg, Germany.
Department of Pediatrics and Children's Cancer Research Center (CCRC), Technische Universität München, Munich, Germany.
Children's Cancer Research Institute, Vienna, Austria.
Cellular Biotechnology Unit, Instituto de Salud Carlos III, Madrid, Spain.
Centre for Craniofacial and Regenerative Biology, King's College London, London, UK.
Division of Oncology, Adhesion and Metastasis Laboratory, Center for Applied Medical Research, University of Navarra, Pamplona, Spain.
Institute of Biostructures and Bioimaging (IBB), Italian National Research Council (CNR), Turin, Italy.
Department of Oncology and Metabolism, University of Sheffield, Sheffield, UK.
Department of General, Visceral and Transplantation Surgery, University of Heidelberg, Heidelberg, Germany.
Université de Nantes, Inserm, U1238, Nantes, France.
Department of Pharmaceutical Technology, Faculty of Pharmacy, University of Coimbra, Coimbra, Portugal.
Instituto de Investigación Sanitaria del Principado de Asturias, Oviedo, Spain.
CIBER en oncología (CIBERONC), Madrid, Spain.
Department of Drug Design, University of Groningen, Groningen, The Netherlands.
Department of Oral and Maxillofacial Diseases, University of Helsinki, Helsinki, Finland.


References:
Not available.
Sarcoma treatment in the era of molecular medicine

Sarcomas are heterogeneous and clinically challenging soft tissue and bone cancers. Although constituting only 1% of all human malignancies, sarcomas represent the second most common type of solid tumors in children and adolescents and comprise an important group of secondary malignancies. More than 100 histological subtypes have been characterized to date, and many more are being discovered due to molecular profiling. Owing to their mostly aggressive biological behavior, relative rarity, and occurrence at virtually every anatomical site, many sarcoma subtypes are in particular difficult-to-treat categories. Current multimodal treatment concepts combine surgery, polychemotherapy (with/without local hyperthermia), irradiation, immunotherapy, and/or targeted therapeutics. Recent scientific advancements have enabled a more precise molecular characterization of sarcoma subtypes and revealed novel therapeutic targets and prognostic/predictive biomarkers. This review aims at providing a comprehensive overview of the latest advances in the molecular biology of sarcomas and their effects on clinical oncology; it is meant for a broad readership ranging from novices to experts in the field of sarcoma.
Sarcoma treatment in the era of molecular medicine

▼    Translational Molecular Imaging in Cancer
▼    Molecular imaging for personalized therapy in oncology
Sarcoma treatment in the era of molecular medicine

Filter those results▼
Query:  [X]
Options:
   Extended  
   IBB affiliation
 
Authors:  [X]
Paper type:  [X]
Start date:  [X]
End date:  [X]
Site:
[Clear form]
Select the year: 
Other filter: ([btitle,keywords] "Bone Sarcoma" OR [bt ...

Sort by:   date ▼▲   title ▲ ▼   journal ▲ ▼   authors ▲ ▼   I.F. ▲ ▼
Sivaccumar JP, Leonardi A, Iaccarino E, Corvino G, Sanguigno L, Chambery A, Russo R, Valletta M, Latino D, Capasso D, Doti N, Ruvo M, Sandomenico A
* Development of a New Highly Selective Monoclonal Antibody against Preferentially Expressed Antigen in Melanoma (PRAME) and Identification of the Target Epitope by Bio-Layer Interferometry (172 views)
Int J Mol Sc (ISSN: 1422-0067linking, 1422-0067electronic, 1661-6596), 2021 Mar 20; 22(6): N/D-N/D.
Impact Factor: 4.556
View    Export to BibTeX    Export to EndNote

Gogliettino M, Cocca E, Sandomenico A, Gratino L, Iaccarino E, Calvanese L, Rossi M, Palmieri G
* Selective inhibition of acylpeptide hydrolase in SAOS-2 osteosarcoma cells: is this enzyme a viable anticancer target? (184 views)
Mol Biol Rep (ISSN: 0301-4851linking), 2021 Feb; 48(2): 1505-1519.
Impact Factor: 2.316
View    Export to BibTeX    Export to EndNote

Tornatore L, Capece D, Sandomenico A, Verzella D, Vecchiotti D, Zazzeroni F, Ruvo M, Franzoso G
* The Screening of Combinatorial Peptide Libraries for Targeting Key Molecules or Protein-Protein Interactions in the NF-κB Pathway (109 views)
Methods Mol Biol (ISSN: 1064-3745linking, 1940-6029electronic), 2021; 2366: 343-356.
Impact Factor: 1.17
View    Export to BibTeX    Export to EndNote

Camorani S, Passariello M, Agnello L, Esposito S, Collina F, Cantile M, Di Bonito M, Ulasov IV, Fedele M, Zannetti A, De Lorenzo C, Cerchia L
* Aptamer targeted therapy potentiates immune checkpoint blockade in triple-negative breast cancer (191 views) (PDF 79 views)
J Exp Clin Canc Res (ISSN: 0392-9078linking, 1756-9966, 1756-9966electronic), 2020 Sep 7; 39(1): 180-180.
Impact Factor: 7.068
View    Export to BibTeX    Export to EndNote

De Simone G
* Targeted treatment of anaerobic cancer. Patent evaluation of US2016279084 and US2017056350 (368 views)
Expert Opin Ther Pat (ISSN: 1744-7674electronic, 1354-3776linking), 2019 Jan; 29(1): 1-6.
Impact Factor: 3.699
View    Export to BibTeX    Export to EndNote

Camorani S, Fedele M, Zannetti A, Cerchia L
* TNBC Challenge: Oligonucleotide Aptamers for New Imaging and Therapy Modalities (543 views) (PDF 153 views)
Pharmaceuticals (ISSN: 1424-8247print, 1424-8247linking), 2018 Nov 13; 11(4): N/D-N/D.
Impact Factor: 4.286
View    Export to BibTeX    Export to EndNote

Cuocolo A, Pappata S, Zampella E, Assante R
* Advances in SPECT Methodology (510 views)
Int Rev Neurobiol (ISSN: 0074-77429780128154182, 2162-5514electronic), 2018 Sep; 141: 77-96.
Impact Factor: 3.36
View    Export to BibTeX    Export to EndNote

Calce E, Monfregola L, Saviano M, De Luca S
* HER2-mediated anticancer drug delivery: strategies to prepare targeting ligands highly specific for the receptor (956 views)
Curr Med Chem (ISSN: 0929-8673, 1875-533x, 1875-533xelectronic), 2015 May 20; 22(21): 2525-2538.
Impact Factor: 3.455
View    Export to BibTeX    Export to EndNote

Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F, Pepe S
* Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications (678 views)
Head Neck-J Sci Spec (ISSN: 1043-3074), 2015; 37(5): 763-770.
Impact Factor: 2.76
View    Export to BibTeX    Export to EndNote

Accardo A, Aloj L, Aurilio M, Morelli G, Tesauro D
* Receptor binding peptides for target-selective delivery of nanoparticles encapsulated drugs (1329 views)
Int J Nanomed (ISSN: 1178-2013, 1176-9114, 1176-9114linking), 2014 Mar 27; 9(1): 1537-1557.
Impact Factor: 4.383
View    Export to BibTeX    Export to EndNote

Musumeci D, Roviello GN, Montesarchio D
* An overview on HMGB1 inhibitors as potential therapeutic agents in HMGB1-related pathologies (713 views)
Pharmacol Ther (ISSN: 0163-7258, 0163-7258linking), 2014 Mar; 141(3): 347-357.
Impact Factor: 9.723
View    Export to BibTeX    Export to EndNote

11 Records (11 excluding Abstracts).
Total impact factor: 46.776 (46.776 excluding Abstracts).
Total 5 year impact factor: 35.853 (35.853 excluding Abstracts).

Last modified by Gennaro Angrisano on Thursday 14 January 2021, 14:39:51
147 views. Last view on Thursday 16 January 2025, 18:10:00